Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted inducement equity awards on November 1, 2025 to 18 new non-executive employees under its 2025 Inducement Plan.
The board’s independent Compensation Committee approved the awards in accordance with Nasdaq Listing Rule 5635(c)(4). In aggregate the new hires received 7,301 time-based restricted stock units (RSUs), which vest in four equal annual installments on each of the first through fourth anniversaries of the grant date, subject to continued employment.
Madrigal Pharmaceuticals (NASDAQ:MDGL) ha concesso premi azionari di incentivo all’assunzione il 1 novembre 2025 a 18 nuovi dipendenti non esecutivi nell’ambito del Piano di Incentivi 2025.
Il comitato indipendente di remunerazione del consiglio ha approvato i premi conformemente alla Nasdaq Listing Rule 5635(c)(4).
Nel complesso, i nuovi assunti hanno ricevuto 7.301 unità azionarie vincolate basate sul tempo (RSU), che maturano in quattro rate annuali uguali sui primi quattro anniversari della data di conferimento, soggette a continuazione del rapporto di lavoro.
Madrigal Pharmaceuticals (NASDAQ:MDGL) otorgó premios de acciones de inducción el 1 de noviembre de 2025 a 18 nuevos empleados no directivos bajo su Plan de Inducción 2025.
El Comité independiente de Compensación de la junta aprobó los premios de acuerdo con la Regla de Listado 5635(c)(4) de Nasdaq.
En conjunto, los nuevos empleados recibieron 7.301 unidades de acciones restringidas basadas en el tiempo (RSU), que se consolidan/vest en cuatro cuotas anuales iguales en cada uno de los primeros cuatro aniversarios de la fecha de otorgamiento, sujeto a la continuidad en su empleo.
Madrigal Pharmaceuticals (NASDAQ:MDGL)는 2025년 11월 1일에 18명의 신규 비임원 직원에게 인덕션 주식 보상금을 부여했습니다.
이사회 독립 보상 위원회는 Nasdaq Listing Rule 5635(c)(4)에 따라 보상을 승인했습니다.
총액으로 신규 채용자들은 시간 기반의 제한 주식단위(RSU) 7,301주를 받았으며, 이는 수여일의 첫 번째부터 네 번째 해까지 매년 같은 금액으로 vest되며, 고용이 유지되는 경우에만 적용됩니다.
Madrigal Pharmaceuticals (NASDAQ:MDGL) a accordé des primes d’actions d’induction le 1er novembre 2025 à 18 nouveaux employés non cadres dans le cadre de son Plan d’induction 2025.
Le comité indépendant de rémunération du conseil a approuvé les primes conformément à la Nasdaq Listing Rule 5635(c)(4).
Au total, les nouveaux employés ont reçu 7 301 unités d’actions restreintes basées sur le temps (RSU), qui s’acquièrent en quatre versements annuels égaux lors du premier au quatrième anniversaire de la date d’octroi, sous réserve du maintien de l’emploi.
Madrigal Pharmaceuticals (NASDAQ:MDGL) hat am 1. November 2025 induzement-Aktionsprämien an 18 neue nicht-führungskräfte Mitarbeiter im Rahmen des Induktionsplans 2025 gewährt.
Der unabhängige Vergütungs-Ausschuss des Vorstands genehmigte die Zuwendungen gemäß der Nasdaq Listing Rule 5635(c)(4).
Insgesamt erhielten die neuen Mitarbeitenden 7.301 zeitbasierte Restricted Stock Units (RSUs), die in vier gleichen Jahresraten am ersten bis vierten Jahrestag der Gewährung vesten, vorbehaltlich einer fortgesetzten Beschäftigung.
Madrigal Pharmaceuticals (NASDAQ:MDGL) منحت جوائز أسهم تحفيزية للانضمام في 1 نوفمبر 2025 لـ 18 موظفاً جديداً غير تنفيذيين بموجب خطة الحافز لعام 2025.
وافقت لجنة التعويض المستقلة في المجلس على الجوائز وفقاً لـ قاعدة إدراج ناسداك 5635(c)(4).
إجمالياً، تلقى الموظفون الجدد 7,301 وحدة أسهم مقيدة زمنياً (RSUs)، التي تتحقق vesting لها على أربع دفعات سنوية متساوية في كل من الذكرى الأولى حتى الرابعة لتاريخ المنح، رهناً باستمرار العمل.
- None.
- None.
CONSHOHOCKEN, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 1, 2025 to 18 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards were granted as inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 7,301 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
What did Madrigal (MDGL) announce on November 6, 2025 about employee equity awards?
How do the 7,301 RSUs granted by MDGL vest and when do they begin vesting?
Were Madrigal’s inducement awards approved under Nasdaq rules for MDGL?
How many employees received inducement awards from Madrigal (MDGL)?
Do the MDGL RSU awards require continued employment to vest?
Are the inducement awards part of Madrigal’s 2025 Inducement Plan for MDGL?
